Company intelligence / Profile preview
XYone Therapeutics
Canton, MA, United Statesxyonetx.com ↗
- Ownership
- Private
- Development stage
- Clinical
01
Overview
XYone is a clinical-stage biopharmaceutical company that has developed novel proprietary ADC drugs targeting MUC1, an oncoprotein overexpressed in over 80% of epithelial cancers. The company has successfully out-licensed two portfolio assets, with one being licensed to Roche/Poseida Therapeutics for CAR technology applications in solid tumors. Their first ADC drug has been selected for the NCI NExT program, with the National Cancer Institute fully funding its development, manufacturing, and FDA approval process without taking equity or commercial rights.[3]
- Therapeutic areas
- Oncology
- Modalities
- Antibody drug conjugate (ADC)Bispecific antibodyCAR-T
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Roche/Poseida TherapeuticsNational Cancer Institute (NCI NExT program)
Beyond the preview
Go deeper on XYone Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XYone Therapeutics.